Based on the study of 3,219 cases of first admissions to the Urology Department of Wilhelminen Hospital of Vienna, Austria, the problem of stone formation in the upper urinary tract has been statistically investigated. Taking into account the size of the basic populations, it is found that there are about twice as many stone-carrier males than there are females. The left and the right side are stricken with equal frequency, simultaneous bilateral stones are found in only about 15% of thelithiasis cases. Further, whereas for females the incidence of stone formation remains constant from age 20 upwards (the 50–59 age group excepted), for males there is linear increase until about 40–49, after which it remains constant until 69. After this age, there is a significant decrease again. Correlation coefficients between renal lithiasis on the one hand and biliary lithiasis, peptic ulcers and diabetes mellitus on the other are all negligibly small. It is inferred that in the aetiology of stone formation in the upper urinary tract, the conditions prevailing at the site of stone-formation are of greater importance than general metabolic disturbances. It is suggested that more attention be paid to the study of the local conditions.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.